Compagnie Lombard Odier SCmA Purchases 500 Shares of Boston Scientific Co. (NYSE:BSX)

Compagnie Lombard Odier SCmA lifted its position in shares of Boston Scientific Co. (NYSE:BSX) by 9.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,902 shares of the medical equipment provider’s stock after acquiring an additional 500 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Boston Scientific were worth $595,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in BSX. TFC Financial Management Inc. increased its position in shares of Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 210 shares in the last quarter. Colonial Trust Co SC boosted its holdings in Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Investment Management Corp VA ADV purchased a new stake in Boston Scientific in the fourth quarter worth approximately $25,000. Sunbeam Capital Management LLC purchased a new stake in Boston Scientific in the fourth quarter worth approximately $26,000. Finally, Ameriflex Group Inc. purchased a new stake in Boston Scientific in the fourth quarter worth approximately $31,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 56,372 shares of the business’s stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total value of $5,799,551.36. Following the sale, the executive vice president now directly owns 178,342 shares in the company, valued at $18,347,824.96. The trade was a 24.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of the business’s stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the sale, the executive vice president now owns 22,235 shares in the company, valued at approximately $2,269,304.10. This trade represents a 43.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 411,970 shares of company stock worth $42,406,693. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 1.0%

Shares of BSX stock opened at $98.43 on Friday. The company has a market capitalization of $145.62 billion, a price-to-earnings ratio of 78.74, a PEG ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The company’s fifty day moving average price is $100.84 and its 200-day moving average price is $98.62. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Boston Scientific’s revenue for the quarter was up 20.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.56 EPS. Sell-side analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BSX shares. Citigroup restated a “buy” rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Argus set a $130.00 target price on shares of Boston Scientific in a report on Tuesday, February 18th. Evercore ISI raised their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an “outperform” rating in a report on Thursday, April 24th. Truist Financial raised their target price on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a “buy” rating in a report on Thursday, April 24th. Finally, Royal Bank of Canada lifted their price target on shares of Boston Scientific from $116.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, April 24th. Twenty-one investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $116.00.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.